Top

International Journal of Clinical Oncology

Published in:

Open Access 01-02-2018 | Original Article

Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases

Authors: Jingtai Zhi, Jingzhu Zhao, Ming Gao, Yi Pan, Jianghua Wu, Yigong Li, Dapeng Li, Yang Yu, Xiangqian Zheng

Published in: International Journal of Clinical Oncology | Issue 1/2018

Abstract

Background

The incidence of papillary thyroid microcarcinoma (PTMC) has been increasing globally in the past few decades. PTMC does not have a distinctive morphology that results in differences in biological behavior. The aim of this study was to classify PTMCs according to the morphological features and explore the relationship with clinicopathological characteristics. Additionally, we sought to evaluate whether different variants of PTMC can be an independent predictor for lymph mode metastasis when considering other risk factors.

Methods

Between December 2014 and December 2015, 1041 PTMC cases undergoing surgical resection at Tianjin Medical University Cancer Institute and Hospital were reviewed retrospectively. Statistical analysis was performed to investigate the independent factors for lymph node metastasis in PTMC.

Results

Conventional variant PTMC (CPTMC), follicular variant PTMC (FPTMC), and encapsulated variant PTMC (EnPTMC) were major variants in PTMC, collectively accounting for 96.7% of the entire PTMC cohort.There were significant differences in clinicopathological characteristics among the three major variants. The frequency of aggressive parameters was significantly different among the three variants, including tumor size, minimal extrathyroidal extension (minimal ETE), and lymph node metastasis (all P < 0.05), being highest in CPTMC, lowest in EnPTMC, and intermediate in FPTMC. FPTMC (OR = 0.642, P = 0.003) and EnPTMC (OR = 0.540, P = 0.041) were independent protective factors for lymph node metastasis (LNM). In contrast, male gender (OR = 1.836, P = 0.000), age less than 45 years (OR = 1.457, P = 0.009), tumor size greater than 0.5 cm (OR = 1.453, P = 0.007), calcification (OR = 1.465, P = 0.016), minimal ETE (OR = 1.801, P = 0.001), and multifocality (OR = 1.721, P = 0.000) were independent risk factors for LNM.

Conclusions

The present study demonstrates the distinct biological behaviors of the three major PTMC variants and establishes an aggressive order of CPTMC ≫ FPTMC > EnPTMC. It is necessary to take into consideration variant-related risks and other independent predictors for the determination of lymphadenectomy in patients with PTMC.

Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295(18):2164–2167. doi:10.1001/jama.295.18.2164 CrossRefPubMed

Lin JD (2010) Increased incidence of papillary thyroid microcarcinoma with decreased tumor size of thyroid cancer. Med Oncol (Northwood, London, England) 27(2):510–518. doi:10.1007/s12032-009-9242-8 CrossRef

Chen AY, Jemal A, Ward EM (2009) Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 115(16):3801–3807. doi:10.1002/cncr.24416 CrossRefPubMed

Jung CK, Little MP, Lubin JH et al (2014) The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 99(2):E276–E285. doi:10.1210/jc.2013-2503 CrossRefPubMed

Pedrazzini L, Baroli A, Marzoli L et al (2013) Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up. Minerva Endocrinol 38(3):269–279PubMed

Siddiqui S, White MG, Antic T et al (2016) Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid 26(6):807–815. doi:10.1089/thy.2015.0429 CrossRefPubMed

Soares P, Celestino R, Gaspar da Rocha A et al (2014) Papillary thyroid microcarcinoma: how to diagnose and manage this epidemic? Int J Surg Pathol 22(2):113–119. doi:10.1177/1066896913517394 CrossRefPubMed

Sak SD (2015) Variants of papillary thyroid carcinoma: multiple faces of a familiar tumor. Turk Patoloji Dergisi 31(Suppl 1):34–47. doi:10.5146/tjpath.2015.01313 PubMed

Shi X, Liu R, Basolo F et al (2016) Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab 101(1):264–274. doi:10.1210/jc.2015-2917 CrossRefPubMed

10.

Jun HH, Kim SM, Hong SW et al (2014) Warthin-like variant of papillary thyroid carcinoma: single institution experience. ANZ J Surg. doi:10.1111/ans.12725

11.

Kazaure HS, Roman SA, Sosa JA (2012) Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol 19(6):1874–1880. doi:10.1245/s10434-011-2129-x CrossRefPubMed

12.

Moreno A, Rodriguez JM, Sola J et al (1996) Encapsulated papillary neoplasm of the thyroid: retrospective clinicopathological study with long term follow up. Eur J Surg Acta Chir 162(3):177–180

13.

Lam AK, Lo CY, Lam KS (2005) Papillary carcinoma of thyroid: a 30-yr clinicopathological review of the histological variants. Endocr Pathol 16(4):323–330CrossRefPubMed

14.

Nikiforov YE, Erickson LA, Nikiforova MN et al (2001) Solid variant of papillary thyroid carcinoma: incidence, clinical–pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol 25(12):1478–1484CrossRefPubMed

15.

Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133. doi:10.1089/thy.2015.0020 CrossRefPubMedPubMedCentral

16.

Malandrino P, Russo M, Regalbuto C et al (2016) Outcome of the diffuse sclerosing variant of papillary thyroid cancer: a meta-analysis. Thyroid 26(9):1285–1292. doi:10.1089/thy.2016.0168 CrossRefPubMed

17.

Liu LS, Liang J, Li JH et al (2016) The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a meta-analysis. Eur Arch Oto-Rhino-Laryngol. doi: 10.1007/s00405-016-4302-0

18.

Zhang L, Yang J, Sun Q et al (2016) Risk factors for lymph node metastasis in papillary thyroid microcarcinoma: older patients with fewer lymph node metastases. Eur J Surg Oncol 42(10):1478–1482. doi: 10.1016/j.ejso.2016.07.002

19.

Thompson LD (2016) Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: a name change to Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features would help prevent overtreatment. Mod Pathol 29(7):698–707. doi:10.1038/modpathol.2016.65 CrossRefPubMed

20.

Patel KN (2016) Noninvasive encapsulated follicular variant of papillary thyroid “cancer” (or not): time for a name change. JAMA Oncol 2(8):1005–1006. doi:10.1001/jamaoncol.2016.0714 CrossRefPubMed

21.

Rivera M, Tuttle RM, Patel S et al (2009) Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). Thyroid 19(2):119–127. doi:10.1089/thy.2008.0303 CrossRefPubMed

22.

Tunca F, Sormaz IC, Iscan Y et al (2015) Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma. J Endocrinol Invest 38(12):1327–1334. doi:10.1007/s40618-015-0376-6 CrossRefPubMed

23.

Lin HW, Bhattacharyya N (2010) Clinical behavior of follicular variant of papillary thyroid carcinoma: presentation and survival. Laryngoscope 120(Suppl 4):S163. doi:10.1002/lary.21627 CrossRefPubMed

24.

Mao Y, Xing M (2016) Recent incidences and differential trends of thyroid cancer in the USA. Endocr Relat Cancer 23(4):313–322. doi:10.1530/erc-15-0445 CrossRefPubMedPubMedCentral

25.

Sugitani I, Toda K, Yamada K et al (2010) Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 34(6):1222–1231. doi:10.1007/s00268-009-0359-x CrossRefPubMed

26.

Miyauchi A (2016) Clinical trials of active surveillance of papillary microcarcinoma of the thyroid. World J Surg 40(3):516–522. doi:10.1007/s00268-015-3392-y CrossRefPubMedPubMedCentral

27.

Moon HJ, Kim EK, Chung WY et al (2011) Minimal extrathyroidal extension in patients with papillary thyroid microcarcinoma: is it a real prognostic factor? Ann Surg Oncol 18(7):1916–1923. doi:10.1245/s10434-011-1556-z CrossRefPubMed

28.

Lu ZZ, Zhang Y, Wei SF et al (2015) Outcome of papillary thyroid microcarcinoma: study of 1,990 cases. Mol Clin Oncol 3(3):672–676. doi:10.3892/mco.2015.495 CrossRefPubMedPubMedCentral

29.

Fukuoka O, Sugitani I, Ebina A et al (2016) Natural history of asymptomatic papillary thyroid microcarcinoma: time-dependent changes in calcification and vascularity during active surveillance. World J Surg 40(3):529–537. doi:10.1007/s00268-015-3349-1 CrossRefPubMed

Title: Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases
Authors: Jingtai Zhi
Jingzhu Zhao
Ming Gao
Yi Pan
Jianghua Wu
Yigong Li
Dapeng Li
Yang Yu
Xiangqian Zheng
Publication date: 01-02-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 1/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1170-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

The 5-year outcomes of moderately hypofractionated radiotherapy (66 Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study

Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan

Significance of multiple preoperative laboratory abnormalities as prognostic indicators in patients with urothelial carcinoma of the upper urinary tract following radical nephroureterectomy

Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance

HPV vaccination in Japan: results of a 3-year follow-up survey of obstetricians and gynecologists regarding their opinions toward the vaccine

The use of neoadjuvant therapy for resectable locally advanced thoracic esophageal squamous cell carcinoma in an analysis of 5016 patients from 305 designated cancer care hospitals in Japan

Keynote webinar | Spotlight on antibody–drug conjugates in cancer